Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (10) 10
life sciences & biomedicine (9) 9
female (8) 8
humans (8) 8
male (8) 8
abridged index medicus (6) 6
aged (6) 6
middle aged (6) 6
risk factors (6) 6
atherosclerosis (5) 5
research (5) 5
analysis (4) 4
anticholesteremic agents - therapeutic use (4) 4
cardiac & cardiovascular systems (4) 4
cardiovascular system & cardiology (4) 4
cholesterol, ldl - blood (4) 4
diabetes (4) 4
double-blind method (4) 4
treatment outcome (4) 4
adamantane - analogs & derivatives (3) 3
adult (3) 3
aged, 80 and over (3) 3
antibodies, monoclonal - therapeutic use (3) 3
cardiovascular diseases (3) 3
clinical trials (3) 3
diabetes mellitus, type 2 - drug therapy (3) 3
follow-up studies (3) 3
peripheral vascular disease (3) 3
proprotein convertase 9 - antagonists & inhibitors (3) 3
risk assessment (3) 3
type 2 diabetes (3) 3
11 medical and health sciences (2) 2
1103 clinical sciences (2) 2
1117 public health and health services (2) 2
adamantane - adverse effects (2) 2
adamantane - therapeutic use (2) 2
antibodies, monoclonal - adverse effects (2) 2
anticholesteremic agents - adverse effects (2) 2
atherosclerosis - drug therapy (2) 2
cardiovascular system & hematology (2) 2
care and treatment (2) 2
cholesterol (2) 2
cholesterol, ldl (2) 2
clinical trial (2) 2
dipeptides - adverse effects (2) 2
dipeptides - therapeutic use (2) 2
dipeptidyl-peptidase iv inhibitors - therapeutic use (2) 2
endocrinology & metabolism (2) 2
general & internal medicine (2) 2
health risk assessment (2) 2
heart attacks (2) 2
hypoglycemia (2) 2
hypoglycemia - prevention & control (2) 2
kexin (2) 2
lipoprotein (2) 2
lipoproteins (2) 2
low density lipoprotein (2) 2
medicine, general & internal (2) 2
patients (2) 2
proportional hazards models (2) 2
proprotein convertase 9 - metabolism (2) 2
statins (2) 2
subtilisin (2) 2
usage (2) 2
1102 cardiorespiratory medicine and haematology (1) 1
1102 cardiovascular medicine and haematology (1) 1
activities of daily living (1) 1
adamantane - administration & dosage (1) 1
adolescent (1) 1
albuminuria - diagnosis (1) 1
ambulatory care - methods (1) 1
amputation (1) 1
angina (1) 1
antibodies, monoclonal (1) 1
antibodies, monoclonal, humanized (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
anticholesteremic agents (1) 1
arteriosclerosis (1) 1
atherosclerosis - pathology (1) 1
atherosclerosis - psychology (1) 1
biomarkers - blood (1) 1
biomarkers - urine (1) 1
biopsy clip (1) 1
biopsy marker (1) 1
blood cholesterol (1) 1
blood sugar (1) 1
body mass index (1) 1
breast biopsy (1) 1
breast imaging (1) 1
cardiology (1) 1
cardiovascular (1) 1
cardiovascular disease (1) 1
cerebral infarction (1) 1
chest pain (1) 1
chest pain - diagnosis (1) 1
chest pain - physiopathology (1) 1
chest pain - therapy (1) 1
child (1) 1
children & youth (1) 1
cholesterol, ldl - drug effects (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
by Giugliano, Robert P and Pedersen, Terje R and Park, Jeong-Gun and De Ferrari, Gaetano M and Gaciong, Zbigniew A and Ceska, Richard and Toth, Kalman and Gouni-Berthold, Ioanna and Lopez-Miranda, Jose and Schiele, François and Mach, François and Ott, Brian R and Kanevsky, Estella and Pineda, Armando Lira and Somaratne, Ransi and Wasserman, Scott M and Keech, Anthony C and Sever, Peter S and Sabatine, Marc S and FOURIER Investigators
The Lancet (British edition), ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1962 - 1971
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypercholesterolemia - blood | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Cholesterol, LDL - drug effects | Male | Treatment Outcome | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Patient Safety | Aged, 80 and over | Adult | Cholesterol, LDL - blood | Female | Aged | Blood cholesterol | Monoclonal antibodies | Low density lipoproteins | Lipoproteins (low density) | Inhibitor drugs | Clinical trials | Cardiovascular disease | Lipids | Secondary analysis | Drug therapy | Low density lipoprotein | Statins | Cholesterol | Risk factors | Myocardial infarction | Heart attacks | Laboratories | Angina | Atherosclerosis | Safety | Cerebral infarction | Stroke | Effectiveness | Health risks | Triglycerides | Subtilisin | Patients | Kexin | Arteriosclerosis | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Cognitive Function in a Randomized Trial of Evolocumab
by Giugliano, Robert P and Mach, François and Zavitz, Kenton and Kurtz, Christopher and Im, Kyungah and Kanevsky, Estella and Schneider, Jingjing and Wang, Huei and Keech, Anthony and Pedersen, Terje R and Sabatine, Marc S and Sever, Peter S and Robinson, Jennifer G and Honarpour, Narimon and Wasserman, Scott M and Ott, Brian R and EBBINGHAUS Investigators
The New England journal of medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 7, pp. 633 - 643
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Memory - drug effects | Atherosclerosis - drug therapy | Prospective Studies | Double-Blind Method | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Self-Assessment | Antibodies, Monoclonal - therapeutic use | Male | Cognition - drug effects | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Atherosclerosis - psychology | Aged, 80 and over | Adult | Cholesterol, LDL - blood | Female | Aged | Psychological Tests | Drug Therapy, Combination | Treatment outcome | Usage | Analysis | Statins | Lipoproteins (low density) | Executive function | Cognitive ability | Clinical trials | Subtilisin | Low density lipoprotein | Evidence-based medicine | Cholesterol | Kexin | Cognition & reasoning | Short term memory | Health risk assessment | Spatial memory | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Predisposing factors for any and major hypoglycemia with saxagliptin versus placebo and overall: Analysis from the savor-TIMI 53 trial
by Cahn, Avivit and Raz, Itamar and Mosenzon, Ofri and Leibowitz, Gil and Yanuv, Ilan and Rozenberg, Aliza and Iqbal, Nayyar and Hirshberg, Boaz and Sjostrand, Mikaela and Stahre, Christina and Im, KyungAh and Kanevsky, Estella and Scirica, Benjamin M and Bhatt, Deepak L and Braunwald, Eugene
Diabetes care, ISSN 0149-5992, 08/2016, Volume 39, Issue 8, pp. 1329 - 1337
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Insulin, Short-Acting - adverse effects | Multivariate Analysis | Follow-Up Studies | Insulin, Short-Acting - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Renal Insufficiency - prevention & control | Hypoglycemia - prevention & control | Renal Insufficiency - chemically induced | Hypoglycemic Agents - administration & dosage | Female | Sulfonylurea Compounds - administration & dosage | Glyburide - administration & dosage | Adamantane - administration & dosage | Hypoglycemia - chemically induced | Glyburide - adverse effects | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Body Mass Index | Dipeptides - adverse effects | Risk Factors | Proportional Hazards Models | Insulin - administration & dosage | Sulfonylurea Compounds - adverse effects | Dipeptides - administration & dosage | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Type 2 diabetes | Physicians | Practice | Dosage and administration | Research | Hypoglycemia | Patients | Health aspects | Risk factors | Saxagliptin | Heart attacks | Diabetes | Glucose | Insulin | Risk assessment | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Long-term safety and efficacy of breast biopsy markers in clinical practice
by Smith, Sharon and Taylor, Clayton R and Kanevsky, Estella and Povoski, Stephen P and Hawley, Jeffrey R
Expert review of medical devices, ISSN 1743-4440, Volume ahead-of-print, Issue ahead-of-print, pp. 1 - 7
device safety | biopsy marker | breast imaging | breast biopsy | Biopsy clip | Engineering | Technology | Engineering, Biomedical | Science & Technology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
by Bonaca, Marc P and Nault, Patrice and Giugliano, Robert P and Keech, Anthony C and Pineda, Armando Lira and Kanevsky, Estella and Kuder, Julia and Murphy, Sabina A and Jukema, J Wouter and Lewis, Basil S and Tokgozoglu, Lale and Somaratne, Ransi and Sever, Peter S and Pedersen, Terje R and Sabatine, Marc S
Circulation (New York, N.Y.), ISSN 0009-7322, 01/2018, Volume 137, Issue 4, pp. 338 - 350
atherosclerosis | amputation | cholesterol, LDL | evolocumab | peripheral arterial disease | PCSK9 protein, human | intermittent claudication | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Dyslipidemias - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Serine Proteinase Inhibitors - therapeutic use | Antibodies, Monoclonal, Humanized | Dyslipidemias - blood | Time Factors | Serine Proteinase Inhibitors - adverse effects | Amputation | Peripheral Arterial Disease - blood | Cholesterol, LDL - blood | Female | Dyslipidemias - diagnosis | Dyslipidemias - drug therapy | Limb Salvage | Down-Regulation | Risk Factors | Treatment Outcome | Biomarkers - blood | Proprotein Convertase 9 - metabolism | Anticholesteremic Agents - adverse effects | Peripheral Arterial Disease - mortality | Peripheral Arterial Disease - therapy | Anticholesteremic Agents - therapeutic use | Peripheral Arterial Disease - diagnosis | Proprotein Convertase 9 - antagonists & inhibitors | Aged | Cholesterol, LDL | Care and treatment | Research | Peripheral vascular diseases | Cardiovascular diseases | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL
by Cavallari, Ilaria and Patel, Ravi and Bhatt, Deepak and Steg, Philippe and Leiter, Lawrence and McGuire, Darren and Mosenzon, Ofri and Kanevsky, Estella and Im, Kyungah and Raz, Itamar and Braunwald, Eugene and Scirica, Benjamin
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2016, Volume 67, Issue 13, pp. 2083 - 2083
Defibrillators | Diabetes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text 746
: SCAMP® DECREASED NEED FOR ESCALATION OF CRITICAL INTERVENTIONS IN CHILDREN WITH ASTHMA
by Wong, Jackson and Kanevsky, Estella and Agus, Michael and Graham, Dionne and Bartlett, Joshua and Melendez, Elliot
Critical care medicine, ISSN 0090-3493, 12/2014, Volume 42, p. A1540
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
by O'Donoghue, Michelle L and Fazio, Sergio and Giugliano, Robert P and Stroes, Erik S. G and Kanevsky, Estella and Gouni-Berthold, Ioanna and Im, KyungAh and Lira Pineda, Armando and Wasserman, Scott M and Češka, Richard and Ezhov, Marat V and Jukema, J. Wouter and Jensen, Henrik K and Tokgözoğlu, S. Lale and Mach, François and Huber, Kurt and Sever, Peter S and Keech, Anthony C and Pedersen, Terje R and Sabatine, Marc S
Circulation (New York, N.Y.), ISSN 0009-7322, 2019, Volume 139, Issue 12, pp. 1483 - 1492
atherosclerosis | clinical trial | lipoprotein(a) | Atherosclerosis - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Atherosclerosis - drug therapy | Double-Blind Method | Placebo Effect | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Male | Treatment Outcome | Proprotein Convertase 9 - metabolism | Proprotein Convertase 9 - immunology | Anticholesteremic Agents - therapeutic use | Aged, 80 and over | Adult | Cholesterol, LDL - blood | Female | Aged | Lipoprotein(a) - blood | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
by O’Donoghue, Michelle L and Fazio, Sergio and Giugliano, Robert P and Stroes, Erik S.G and Kanevsky, Estella and Gouni-Berthold, Ioanna and Im, KyungAh and Lira Pineda, Armando and Wasserman, Scott M and Češka, Richard and Ezhov, Marat V and Jukema, J Wouter and Jensen, Henrik K and Tokgözoğlu, S Lale and Mach, François and Huber, Kurt and Sever, Peter S and Keech, Anthony C and Pedersen, Terje R and Sabatine, Marc S
Circulation (New York, N.Y.), ISSN 0009-7322, 03/2019, Volume 139, Issue 12, pp. 1483 - 1492
Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Analysis | Risk assessment | Clinical trials | Research | Cardiovascular diseases | Risk factors | Lipoprotein A
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: Observations from the SAVOR-TIMI 53 Trial
by Scirica, Benjamin M and Mosenzon, Ofri and Bhatt, Deepak L and Udell, Jacob A and Steg, Ph Gabriel and McGuire, Darren K and Im, Kyungah and Kanevsky, Estella and Stahre, Christina and Sjöstrand, Mikaela and Raz, Itamar and Braunwald, Eugene
JAMA cardiology, ISSN 2380-6583, 02/2018, Volume 3, Issue 2, pp. 155 - 163
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Diabetic Nephropathies - urine | Biomarkers - urine | Dipeptides - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Hospitalization - statistics & numerical data | Male | Diabetes Mellitus, Type 2 - urine | Renal Insufficiency, Chronic - complications | Glomerular Filtration Rate - physiology | Diabetic Nephropathies - complications | Diabetic Cardiomyopathies - urine | Albuminuria - diagnosis | Adamantane - therapeutic use | Female | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Heart Failure - etiology | Adamantane - analogs & derivatives | Renal Insufficiency, Chronic - urine
Journal Article
Details down arrow
11. Full Text Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction Observations From the SAVOR-TIMI 53 Trial
by Bergmark, Brian A and Bhatt, Deepak L and McGuire, Darren K and Cahn, Avivit and Mosenzon, Ofri and Steg, Ph. Gabriel and Im, KyungAh and Kanevsky, Estella and Gurmu, Yared and Raz, Itamar and Braunwald, Eugene and Scirica, Benjamin M and SAVOR-TIMI Steering Comm I and On behalf of the SAVOR-TIMI 53 Steering Committee and Investigators
Circulation (New York, N.Y.), ISSN 0009-7322, 09/2019, Volume 140, Issue 12, pp. 1004 - 1014
Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study
by Cahn, Avivit and Mosenzon, Ofri and Bhatt, Deepak L and Leibowitz, Gil and Yanuv, Ilan and Rozenberg, Aliza and Iqbal, Nayyar and Hirshberg, Boaz and Stahre, Christina and Im, KyungAh and Kanevsky, Estella and Raz, Itamar
Diabetes, obesity & metabolism, ISSN 1462-8902, 07/2017, Volume 19, Issue 7, pp. 1045 - 1050
hypoglycaemia | type 2 diabetes | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Recurrence | Hypoglycemia - therapy | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Activities of Daily Living | Hypoglycemia - prevention & control | Hypoglycemia - physiopathology | Adamantane - therapeutic use | Female | Meals | Adamantane - adverse effects | Adamantane - analogs & derivatives | Precision Medicine | Severity of Illness Index | Dipeptides - therapeutic use | Dipeptides - adverse effects | Self Report | Combined Modality Therapy - adverse effects | Randomized Controlled Trials as Topic | Diabetes Mellitus, Type 2 - blood | Hypoglycemia - etiology | Aged | Patient Compliance | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Medicine, Experimental | Medical research | Usage | Blood sugar | Analysis | Hypoglycemia | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Regional implementation of a pediatric cardiology chest pain guideline using SCAMPs methodology
by Angoff, Gerald H and Kane, David A and Giddins, Niels and Paris, Yvonne M and Moran, Adrian M and Tantengco, Victoria and Rotondo, Kathleen M and Arnold, Lucy and Toro-Salazar, Olga H and Gauthier, Naomi S and Kanevsky, Estella and Renaud, Ashley and Geggel, Robert L and Brown, David W and Fulton, David R
Pediatrics (Evanston), ISSN 0031-4005, 10/2013, Volume 132, Issue 4, pp. e1010 - e1017
Pediatric cardiology | Clinical practice guideline | SCAMPs | Chest pain | Life Sciences & Biomedicine | Pediatrics | Science & Technology | Follow-Up Studies | Heart Diseases - physiopathology | Practice Guidelines as Topic - standards | Humans | Echocardiography - methods | Ambulatory Care - methods | Electrocardiography - standards | Male | Radiography, Thoracic - standards | Heart Diseases - diagnosis | Young Adult | Chest Pain - physiopathology | Guideline Adherence | Heart Diseases - therapy | Pediatrics - methods | Adolescent | Echocardiography - standards | Female | Chest Pain - diagnosis | Disease Management | Chest Pain - therapy | Child | Electrocardiography - methods | Practice guidelines (Medicine) | Care and treatment | Research | Pediatric research | Analysis | Pain | Clinical medicine | Cardiology | Children & youth | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights